Examples of using Exon in English and their translations into Romanian
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Computer
-
Programming
bevacizumab in the first-line treatment of patients with KRAS exon 2 wild-type mCRC.
T790M alone or exon 20 insertions alone are resistance mechanisms.
A predefined retrospective subset analysis of 143 patients of the 154 patients with wild-type KRAS(exon 2) mCRC was performed,
Patients with additional RAS mutations beyond KRAS exon 2 were unlikely to benefit from the addition of panitumumab to FOLFIRI and a detrimental effect was seen with the addition of panitumumab to FOLFOX in these patients.
The common EGFR activating mutations(Exon 19 deletions; L858R) have robust response data supporting sensitivity to gefitinib;
For the assessment of the RAS status, mutations other than those on exon 2 of the KRAS gene were determined from all evaluable tumour samples within the KRAS exon 2 wild-type population(65%).
The trial resulted in exon 51 skipping and dystrophin restoration in the majority of muscle fibers(60-100%)
several less common EGFR mutations in exon 18(G719X) and exon 21(L861Q) are particularly sensitive to afatinib treatment in non-clinical and clinical settings.
RAS status was evaluable in tumour samples of 407 KRAS exon 2 wild-type patients reflecting 69% of the overall KRAS exon 2 wild-type patient population(592 patients).
The RAS mutant population comprises these 65 patients together with 113 patients with KRAS exon 2 mutant tumours treated before study enrolment was restricted to patients with KRAS exon 2 wild-type mCRC.
After initial experiments that showed that exon skipping and dystrophin restoration was feasible in patient-derived cell cultures and resulted also in functional improvement in the mdx mouse model, exon 51 skipping was tested in clinical trials in DMD patients[47].
bevacizumab in patients with KRAS exon 2 wild-type metastatic colorectal cancer(mCRC).
EGFR mutation(Exon 19 deletion and L858R).
The BO25460(IUNO) study was conducted in 643 patients with advanced NSCLC whose tumors did not harbor an EGFR-activating mutation(exon 19 deletion or exon 21 L858R mutation) and who had not experienced disease progression after four cycles of platinum-based chemotherapy.
who present mutations in the tyrosine kinase domain of the EGFR(exon 19 deletion or exon 21 mutation).
safety of Avastin used in addition to erlotinib in patients with non-squamous NSCLC with EGFR activating mutations(exon 19 deletion or exon 21 L858R mutation) who had not received prior systemic therapy for Stage IIIB/IV or recurrent disease.
Dystrophin positive fibers due to either spontaneous exon skip-ping or a frame-restoring secondary mutation,
The gene consists of exons(funcţional regions of gene),
Deletions of one or more exons of the SMN1 gene;
The instructions we keep, we call exons.